Context: Increasing the use of effective smoking cessation aids could in principle have a
substantial public health impact. The UK government has undertaken several major policy …

Background: Tobacco smoking is the leading preventable cause of morbidity and mortality in
Australia and other developed countries. Of the pharmacological aids that are available for …

Purpose Evaluation of tobacco policy requires high quality and timely data on smoking
cessation behaviour in the general population and in relevant target groups. Electronic …

Objective: To compare the characteristics of smokers who do and do not receive smoking
cessation treatment in primary care. Design: Prospective cohort study using practices …

Objective To assess interest in quitting smoking and quitting activity, and the use of
pharmacotherapy and behavioural cessation support, among Australian smokers between …

Aims To determine the incremental cost effectiveness of nicotine replacement therapy
(NRT), bupropion and varenicline for preventing relapse to smoking when used by abstinent …

Although products for nicotine replacement therapy (NRT) have been available for over 20
years, they have been excluded until recently from state or insurance based health service …

OVERVIEW The proven pharmacotherapies for smoking cessation are nicotine gum, inhaler,
nasal spray, and patch (Hughes, 1996; Hughes et al., 1999) and the non-nicotine therapies …

Whether insurance coverage for smoking-cessation medicines increases quitting rates is
uncertain. In this paper we evaluate the overall effect of a new health plan pharmacy benefit …

Objective: To explore the information received by NRT users; whether patterns of NRT use
are in accordance with recommendations; and to identify the characteristics of those using …